Hematopoietic stem cells have been at the forefront of stem cell research and its applications. Several advancements have occurred in the field of hematopoietic stem cell transplantation since this was first accepted as a treatment for otherwise incurable hematological disorders. The progress in this field is to the extent that it is unfathomable to a single person be it a scientific researcher or a practicing clinician. In this internet era, most patients are also well informed of the utility of stem cells. There is a need to bridge the gap in knowledge of this science between the scientists, physicians and the public at large. This review aims to summarize the advances in hematopoietic stem cell applications.
• Hematopoietic stem cells possess the characteristics of self renewal, differentiation, mobilization and apoptosis.
• The transfer of hematopoietic stem cells to rescue a recipient's hematopoiesis, who has received conditioning with high dose chemotherapy and/or total body irradiation, constitutes hematopoietic stem cell transplantation (HSCT). 
INTRODUCTION
Stem cells and its applications have been center stage of most of the biological research in the past decade or so. Its interest is so because of its widely believed potential applications to the humanity. The benefit and risks have also been an area of debate among the scientists, politicians and the public in general. However, it is up to the scientific community to educate the people about the present applications, ethics and limitations of this science. To 7 and by Sir Thomas in a patient with leukemia in 1969. 8 We have come a long way since this pioneering research. Current estimates of annual number of HSCTs are 55,000 to 60,000 worldwide. Reasons for widespread use include proven efficacy in many diseases, better understanding of the procedure, patient selection, improved stem cell collections, conditioning strategies, better supportive care and developments in the field of matched unrelated transplants and cord blood transplants. This has lead to transplants being done in older and sicker patients with lesser transplantation related morbidity and mortality.
CHANGING SCENARIO OF HEMATOPOIETIC STEM CELL TRANSPLANTATION
In the 1970s, nonmalignant diseases, like aplastic anemia (40%) and immune deficiencies (15%), were the major indications for HSCT. By 1985, leukemias (70%) overtook nonmalignant diseases as an indication of allogeneic HSCT which is so till date. Aplastic anemia and immune deficiencies now account for 5% of allogeneic transplants. Multiple myeloma is the most common (48%) indication of autologous transplants. Non-Hodgkin's lymphoma (28%) and Hodgkin's lymphoma (12%) are next common. Breast carcinoma was the most frequent (40%) carcinoma treated with autologous HSCT in 1994 to 1995. However, the borderline or negative results in most randomized trials and the revelation of fraud in one positive trial 9 have resulted in waning of interest in treating this cancer with this approach. Solid cancers account for 10% of all autologous stem cell transplants.
SOURCE OF STEM CELLS
The stem cell can be obtained from the following sources of the human body.
• Bone marrow (BM): Till recently, all stem cell harvests were done from the bone marrow. The procedure of isolating stem cells from the bone marrow is a painful and tedious process. It is a problem with young donors where this procedure often needs to be done under general anesthesia. Currently, bone marrow is the stem cell source in about 50% of pediatric transplants and less than 15% of adult transplants.
• Peripheral blood hematopoietic stem cells (PBSC):
PBSC is collected from the peripheral blood by leukapheresis after stem cell mobilization using growth factors. These harvests have more progenitor cells and have been shown to have an advantage in terms of faster hematopoietic recovery. Randomized control trials (RCT) have also shown a survival advantage for PBSC compared to BM as a source for HSCT, however at the cost of increased risk of graft versus host disease. 10 It is due to this reason and also the ease of accessibility that there is an increasing trend to use this as a stem cell source. Currently, PBSC accounts for about 70% of related donor and 60% of unrelated donor HSCT. PBSC have been excluded from the purview of the national organ transplant act thereby permitting its sale for transplant purposes.
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• Umbilical cord blood (UCB): UCB is rich in hematopoietic precursors; however the quantity collected from one individual is inadequate to repopulate bone marrow for a normal adult. This can be overcome by double cord transplants, coinfusion of mesenchymal stem cells, direct injection of cord blood into the marrow and other ex vivo cell expansion techniques. UCB cells are immunologically naive and have lower number of T-cells and hence transplant can be carried out even if there is a four out of six HLA match. UCB transplants now account for up to 5% of all transplants. There is an increasing awareness of UCB banks among the public, thanks to the aggressive marketing by private banks. However, the UCB from these private banks is reserved for the same individual in contrast to public banks in some countries where they are available to all. The probability of using one's own UCB for a hematological disorder in childhood where HSCT is required, is to the tune of 1:2500 to 1:200,000. 12, 13 This is the major drawback of private banking.
TYPES OF TRANSPLANT
Hematopoietic stem cell transplants (HSCT) are basically of two types: Autologous and Allogeneic.
• Autologous HSCT involves the intravenous infusion of a patient's own hematopoietic stem cells to rescue the patient from severe bone marrow injury caused by high dose chemotherapy and or radiotherapy as a part of treatment for cancer. This works on the principle that dose escalation of chemotherapy to a point of irreversible myelotoxicity but tolerable due to the replacement of myeloid function with the infused hematopoietic stem cells.
• Allogeneic HSCT on the other hand involves infusion of hematopoietic stem cells from another individual. The type of transplant in common diseases is summarized in Figure 1 . 14 Depending on the donor, allogeneic HSCT can further be subclassified as follows, summarized in 20 Onethird of the patients achieve a CR with a disease free progression of 10 years in a third among these. This demonstrates a potential curability of the disease. However, in the era of newer drugs with higher and deeper responses, there is no definite evidence for early transplant. Currently, myeloma is one of the most frequently treated malignancies with HSCT. Young patient with limited AL-amyloidosis are also candidates for autologous HSCT. Carcinomas and sarcomas: Other malignancies where autologous HSCT has been successfully tried include malignant melanomas, neuroblastoma and germ cell tumors. Besides this autologous HSCT has also been studied in autoimmune diseases, like SLE, rheumatoid arthritis and multiple sclerosis, however no recommendations can be made in the absence of well designed clinical trials.
• Allogeneic HSCT: The application of allogeneic transplants can be mainly divided into nonmalignant and malignant causes. Nonmalignant conditions and indications for allogeneic HSCT include the following (Table 2) . Thalassemia is one of the commonest inherited condition for which HSCT is the only curative treatment option. The life of a thalassemic patient is highly miserable with the requirement of frequent blood transfusions and complications of iron overload. All patients with HLA matched related donors should be offered HSCT at the earliest as delay in transplant reduces transplant success due to irreversible damage of iron overload. The indications for HSCT in sickle cell disease are evolving and is currently recommended in age <16 years, recurrent vaso-occlusive episodes (chest or CNS) and sickle cell nephropathy. 21 The success rate is among the best of all disorders offered HSCT. Despite this HSCT is not commonly performed for this disease because of parent's unacceptability to transplant related mortality. Severe combined immunodeficiency (SCID) and Wiskott-Aldrich syndrome are some of the primary immunodeficiency states for which an allogeneic HSCT is life saving. In the absence of a matched sibling donor, alternative donor sources include cord blood, unmodified matched unrelated or T-cell depleted HLAhaplotype/disparate parental grafts in that order. The success 
TIMING OF TRANSPLANT
The timing of transplant is the most important factor in the outcome of HSCT in malignant conditions. In acute myeloid leukemia, there is evidence that allogeneic HSCT in patients younger than 55 years with high risk cytogenetics has survival benefit. It is also the favored option for patients in second complete remission. However, for those without a matched sibling donor, an autologous HSCT is an option in CR2, though it is not curative. 25 Myeloablative allogeneic HSCT is recommended for all adult acute lymphoblastic leukemia risk subgroups in CR1 and CR2. An autologous HSCT can be performed in the absence of a matched donor. 26 In children, the recommendations are to perform an allogeneic HSCT in CR1 for induction failure and in CR2 for early marrow relapse. 27 In the era of tyrosine kinase inhibitors, allogeneic HSCT is reserved for accelerated and blastic phases of chronic myeloid leukemia and for treatment failures due to proven TKI resistance. Transplant is restricted to high-risk patients (17p del/p53 mutation) or relapsed/ refractory chronic lymphocytic leukemia. 28 HSCT for solid cancers is limited by the fact that graft versus tumor effects are not robust. The safety and efficacy also needs to be confirmed in larger RCTs.
NONHEMATOLOGICAL APPLICATIONS OF HEMATOPOIETIC STEM CELLS
Hematopoietic stem cells were believed to have the property of plasticity, i.e. the ability to dedifferentiate into parenchymal cells of the tissue into which they were transplanted. It was assumed that they would have a role in tissue regeneration and this was the reason for their interest in regenerative medicine. HSC probably act by secreting various cytokines and chemokines stimulating proliferation of endogenous native tissue stem cells, inhibiting apoptosis and promoting angiogenesis. However, this has not translated into clinical success. The results with intravenous or intracoronary injections of autologous hematopoietic stem cells (mononuclear cells) in ischemic heart disease have not been up to the expectations, 29 probably because the process of regeneration involving HSC is a very slow process. Cord blood is being studied for these applications too. UCB has been shown to contain unrestricted somatic stem cells (USSCs), mesenchymal stem cells (MSC) and endothelial colony forming cells (ECFC). The bone marrow is also a source of some of these stem cells like mesenchymal stem cells. These stem cells have osteogenic, chondrogenic, and adipogenic differentiation potential. These cells have been shown to have applications in regenerative medicine involving traumatic and skeletal diseases, plastic surgery, type 1 diabetes mellitus, cardiovascular (ischemic heart disease, cardiomyopathies) and neurological diseases (Parkinson's disease, strokes, motor neuron disease, spinal trauma) in preclinical studies. As the ethics in the use of embryonic stem cells is highly debated, exvivo expansion of cord blood may replace embryonic stem cells for these applications in the future. 30, 31 It is for these reasons that it is important to advocate public banking of UCB.
CONCLUSION
The progress in the field of hematopoietic stem cell transplantation has been enormous. The results are getting better with each passing year. Despite this, the cure rates for most diseases are only slightly superior to that was seen in the past. The future lays in enhanced stem cell selection and amplification strategies. We are still far from an ideal, all purpose universal donor cell line, but this goal does not seem impossible.
